MS News That Caught My Eye Last Week: NVG-291, Ocrevus, Tolebrutinib, Tecfidera

MS News That Caught My Eye Last Week: NVG-291, Ocrevus, Tolebrutinib, Tecfidera

312020

MS News That Caught My Eye Last Week: NVG-291, Ocrevus, Tolebrutinib, Tecfidera

Nerve Repair Therapy NVG-291 Safe, Well-tolerated in Healthy People This experimental therapy has a long way to go before it becomes reality. But it’s encouraging that this first step found NVG-291’s side effects to be mild and short-lasting. NVG-291 is designed to promote remyelination by modulating an enzyme called tyrosine phosphatase sigma. Researchers hope to start a Phase 1b/2 clinical trial of NVG-291 with MS patients early next year. A single dose of NVG-291, a…

You must be logged in to read/download the full post.